DWA
BSTC

Dorsey Wright & Associates’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Dorsey Wright & Associates’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-160
Closed -$9K – 374
2019
Q3 		$9K Buy
160
+2
+1% +$116 ﹤0.01% 277
2019
Q2 		$9K Buy
158
+39
+33% +$2.45K ﹤0.01% 275
2019
Q1 		$7K Sell
119
-117
-50% -$7.74K ﹤0.01% 274
2018
Q4 		$14K Buy
+236
New +$14.1K ﹤0.01% 221

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dorsey Wright & Associates's BSTC Position: Q4 2019 in Review

Dorsey Wright & Associates sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2019, closing a stake of 160 shares — an estimated $9K sold.

Dorsey Wright & Associates first reported a position in BSTC in Q4 2018 and held it in 4 quarters. The position peaked at $14K in Q4 2018. 112 funds tracked by Wall St. Rank hold BSTC as of Q4 2019.

  • Dorsey Wright & Associates reported no remaining BioSpecifics Technologies Corp. position as of Q4 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 160 BioSpecifics Technologies Corp. shares in Q4 2019, an estimated $9K.
  • Dorsey Wright & Associates first reported a position in BioSpecifics Technologies Corp. in Q4 2018 and held it in 4 quarters.
  • Dorsey Wright & Associates's BioSpecifics Technologies Corp. position peaked at $14K in Q4 2018.
  • 112 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2019.

Based on Dorsey Wright & Associates's 13F filing for Q4 2019, filed 31 Jan 2020.